Core Insights - On July 4, 2025, Guotai Junan International (01788), Alibaba-W (09988), and SMIC (00981) were the top three stocks by trading volume in the Southbound Stock Connect, with trading amounts of 10.714 billion, 3.571 billion, and 3.184 billion respectively [1] - In the Southbound Stock Connect for the Shenzhen-Hong Kong Stock Connect, Guotai Junan International (01788), Alibaba-W (09988), and Xiaomi Group-W (01810) also led the trading volume, with amounts of 3.641 billion, 3.489 billion, and 2.435 billion respectively [1] Southbound Stock Connect (Shanghai-Hong Kong) - Top active companies by trading volume: - Guotai Junan International (01788): 10.714 billion, net buy of 91.5226 million [2] - Alibaba-W (09988): 3.571 billion, net sell of 334 million [2] - SMIC (00981): 3.184 billion, net buy of 37.2 million [2] - Xiaomi Group-W (01810): 3.087 billion, net sell of 370 million [2] - Meituan-W (03690): 2.379 billion, net sell of 270 million [2] - China Construction Bank (00939): 2.120 billion, net buy of 168 million [2] - XPeng Inc. (09868): 2.108 billion, net buy of 919 million [2] - Tencent Holdings (00700): 1.900 billion, net sell of 145 million [2] - CanSino Biologics (09926): 1.674 billion, net sell of 95.5519 million [2] - Dmall (02586): 1.249 billion, net buy of 30.1596 million [2] Southbound Stock Connect (Shenzhen-Hong Kong) - Top active companies by trading volume: - Guotai Junan International (01788): 3.641 billion, net buy of 50.5414 million [2] - Alibaba-W (09988): 3.489 billion, net sell of 1.153 billion [2] - Xiaomi Group-W (01810): 2.435 billion, net sell of 443 million [2] - SMIC (00981): 1.969 billion, net buy of 39.6 million [2] - Tencent Holdings (00700): 1.777 billion, net sell of 28.7313 million [2] - CanSino Biologics (09926): 1.675 billion, net buy of 19.5 million [2] - Meituan-W (03690): 1.660 billion, net buy of 96.5584 million [2] - XPeng Inc. (09868): 1.480 billion, net sell of 462.813 million [2] - Innovent Biologics (01801): 819 million, net buy of 18.2291 million [2] - China Mobile (00941): 622 million, net buy of 47.7507 million [2]

第一财经记者了解到，信达生物GLP-1类减重创新药玛仕度肽已于7月3日在北京大学人民医院开出 全国首张处方。北京大学人民医院纪立农教授为一位超重并伴有脂肪肝的患者开具处方，标志着该药 物在全国正式进入商业化。 ...

Core Insights - The article highlights the launch of a new weight loss drug, Xinermai (generic name: Masitide Injection), developed by Innovent Biologics, which is the world's first GCG/GLP-1 dual receptor agonist approved for weight management in adults with obesity or overweight [1][3]. Industry Overview - Obesity is increasingly recognized as a chronic metabolic disease in China, with the adult overweight and obesity rate reaching 51.2%. If not effectively addressed, this rate is projected to rise to 70.5% by 2030 [3]. - The use of scientifically-based pharmacological interventions is essential for effective weight management, as evidenced by the clinical trials demonstrating significant weight loss and metabolic improvements with Masitide [3]. Product Details - Masitide's dual-target mechanism enhances weight loss effects compared to single-target GLP-1 drugs, leading to reductions in visceral fat and improvements in hypertension, hyperglycemia, hyperlipidemia, and hyperuricemia [3]. - Clinical trials showed that doses of 4mg and 6mg of Masitide over 32 and 48 weeks resulted in significant weight loss and reductions in waist circumference, blood pressure, blood lipids, blood uric acid, and transaminases [3]. Market Launch and Accessibility - The drug is available for patients through JD Health's platform, allowing them to search for "Xinermai" and connect with local medical institutions for appointments [1][4]. - The innovative injection device for Masitide offers enhanced convenience and safety, featuring a needle-free design and painless injection technology [4]. Strategic Collaboration - JD Health's collaboration with Innovent Biologics aims to leverage its multi-channel advantages and healthcare service capabilities to provide patients with more accessible and scientific weight management solutions [5]. - The launch of Xinermai represents a new treatment option for overweight and obese patients in China, with potential applications expanding into areas like fatty liver and adolescent obesity [5].

Core Viewpoint - The launch of the innovative weight loss drug, Xin'ermei (generic name: Masitide Injection), by Innovent Biologics marks a significant advancement in obesity treatment, being the world's first GCG/GLP-1 dual receptor agonist approved for long-term weight control in adults with obesity or overweight [1][2]. Group 1: Drug Efficacy and Mechanism - Xin'ermei operates through a dual-target mechanism, enhancing weight loss effects and reducing visceral fat compared to GLP-1 single-target drugs, while also improving metabolic issues such as hypertension, hyperglycemia, hyperlipidemia, and hyperuricemia [1]. - Clinical trials demonstrated significant weight loss efficacy with Masitide at dosages of 4mg and 6mg over 32 and 48 weeks in overweight or obese individuals who struggled with weight control through diet and exercise alone [1]. Group 2: Market Launch and Collaboration - The online launch of Xin'ermei on JD Health provides a new treatment option for overweight and obese patients in China, with expectations for broader clinical applications in areas like fatty liver and adolescent obesity as research progresses [2]. - JD Health's collaboration with Innovent Biologics aims to leverage its full-channel advantages and healthcare service capabilities to facilitate the market expansion of innovative drugs, contributing significantly to the scientific weight loss efforts in China [2]. Group 3: Device Innovation - The newly approved Masitide injection device features significant improvements in convenience and safety, including a needle-free design and a disposable mechanism that minimizes risks during use, along with a pain-free injection experience enabled by innovative X-section technology [2].

Investment Rating - The investment rating for Innovent Biologics is "Buy" with a 12-month price target of HK$74.95, indicating a downside potential of 11.4% from the current price of HK$84.60 [9]. Core Insights - Innovent Biologics is focusing on a multi-channel strategy for the launch of mazdutide, targeting hospitals, offline healthcare providers, and online pharmacies to maximize market reach [5][6]. - The company aims to build a competitive barrier for mazdutide through its dual-target mechanism and plans for new indication expansions, including Type 2 Diabetes (T2D) approval expected in the second half of 2025 [6][8]. - Innovent is prioritizing the clinical development of IBI363, with plans to advance multiple indications into registrational trials and a preference for co-development with multinational corporations to enhance its global presence [8]. - The company's go-global strategy is viewed as a long-term process, with a commitment to invest in assets with global potential while maintaining profitability in the China market [8]. Summary by Sections Multi-Channel Coverage for Mazdutide - Innovent has initiated a multi-channel coverage strategy for mazdutide, with the first product batch shipped shortly after approval. The strategy includes targeting hospitals, offline healthcare providers, and online pharmacies [5]. - Management expressed confidence in market demand based on pre-launch feedback and sufficient supply preparation [5]. Competitive Landscape - The pricing strategy for mazdutide positions it at a premium compared to competitors, with a focus on dual-target differentiation and plans for expanding indications [6]. Maximizing Potential of IBI363 - IBI363 is a key focus for Innovent, with plans to advance three priority indications into registrational trials. The company emphasizes quick clinical progress and seeks co-development partnerships to maximize value [8]. Go-Global Strategy - Innovent's go-global strategy is a long-term approach, with plans to invest in assets with global potential while ensuring profitability in the domestic market [8].

Summary of Conference Call on Innovative Drugs and Industry Chain Update Industry Overview - The innovative drug industry in China is accelerating its international expansion, driven by increased investment banking projects, recognition of data from AACR/ASCO conferences, and the engineer dividend. The second-generation immuno-oncology (IO) market has significant potential, expected to reach $200 billion, with China accounting for approximately 40% and leading in R&D progress [1][5][17]. Key Insights - **Profitability through "Borrowing a Boat to Go to Sea" Model**: Innovative drug companies are leveraging this model to achieve profitability, which includes upfront payments, milestone payments for R&D and commercialization, and sales sharing. This provides a clear valuation anchor and allows for DCF cash flow calculations [1][6]. - **PS Valuation Adjustment**: The PS (Price to Sales) valuation for innovative drugs should be adjusted to 5 times, compared to the current 3 times in Hong Kong stocks and 3.5-4 times in A-shares. This indicates a potential valuation recovery space of at least 50% [1][7]. - **CXO Industry Growth**: The CXO (Contract Research Organization) industry is experiencing an upward trend, with significant order growth in CDMO (Contract Development and Manufacturing Organization) companies, with new and existing orders increasing by over 15-20% [1][9]. - **R&D Investment Recovery**: Domestic R&D investment in innovative drugs is gradually recovering, with business development (BD) activities generating upfront payments, becoming a crucial funding source. The large molecule sector, including ADC (Antibody-Drug Conjugates) and bispecific antibodies, is particularly active [1][11]. Additional Important Points - **Supply and Demand Dynamics in Experimental Monkeys**: The supply of experimental monkeys is declining due to aging breeding stock, while demand is closely tied to the innovative drug R&D climate. This creates a widening supply-demand gap, benefiting companies with monkey breeding resources [15][16]. - **Second-Generation IO Market Trends**: The second-generation IO market is a clear trend, with significant sales potential. The PD-1/L2 product from Innovent Biologics is highlighted for its promising performance across various indications, with a projected peak sales of $7 billion [3][18]. - **Investment Opportunities in CXO Sector**: Companies like Zhaoyan, Tigermed, and others in the CXO sector are recommended for investment due to their positive performance and market conditions [1][9]. - **Emerging Companies and Products**: Companies such as Pfizer and Zai Lab are noted for their strategic positioning in the ADC space, with potential for significant valuation increases based on clinical trial outcomes [19][20][21][22]. Conclusion The innovative drug sector in China is poised for growth, with favorable market conditions, strategic international expansion, and a recovery in R&D investments. The second-generation IO market, in particular, presents substantial opportunities for investors, supported by strong clinical data and a favorable regulatory environment.

Summary of Key Points Core Viewpoint - The Hong Kong stock market experienced significant net selling from Northbound trading, with a total of HKD 30.47 billion in net sales on July 3, 2023, indicating a bearish sentiment among investors [1]. Group 1: Northbound Trading Activity - Northbound trading saw a net sell of HKD 30.47 billion, with HKD 18.66 billion from Shanghai Stock Connect and HKD 11.81 billion from Shenzhen Stock Connect [1]. - The most bought stocks included Meituan-W (03690), SMIC (00981), and Innovent Biologics (01801) [1]. - The most sold stocks were Alibaba-W (09988), Tencent (00700), and Guotai Junan International (01788) [1]. Group 2: Individual Stock Performance - Alibaba-W (09988) had a net sell of HKD 32.26 billion, with a total trading volume of HKD 71.91 billion, indicating a strong sell-off [2]. - Meituan-W (03690) received a net buy of HKD 9.87 billion, supported by the announcement of a new initiative to invest in 1,200 "Raccoon Canteens" over three years [4]. - SMIC (00981) saw a net buy of HKD 4.78 billion following the U.S. government's lifting of export restrictions on certain chip design software [5]. Group 3: Sector Insights - The healthcare sector, particularly innovative pharmaceuticals, is expected to benefit from new supportive policies from the National Healthcare Security Administration and the National Health Commission [5]. - The social services sector is projected to experience valuation recovery due to favorable government policies aimed at expanding domestic demand [4]. Group 4: Other Notable Stocks - Xiaomi Group-W (01810) had a net buy of HKD 22.71 million, with the CEO addressing order fulfillment priorities [6]. - Multi-point Smart (02586) received a net buy of HKD 61.61 million as it prepares to apply for a stablecoin license in Hong Kong [5].

Core Viewpoint - The short-term sentiment in the market has improved, with a significant number of stocks reaching their upper limit, indicating a potential recovery in investor confidence [1] Group 1: Market Performance - A total of 61 stocks hit the daily limit, with 14 stocks classified as consecutive limit-up stocks, and 5 of these achieved three consecutive limit-ups or more [1] - The upgrade rate for consecutive limit-up stocks was 41.67%, excluding ST and delisted stocks [1] - Over 3,200 stocks in the market experienced an increase, reflecting a broad-based rally [1] Group 2: Notable Stocks - Chengbang Co. achieved a limit-up, marking its sixth consecutive limit-up [1] - Dazhongnan showcased a "ground-to-sky" performance with 8 limit-ups in 6 days [1] - Haoshanghao reached a historical high with 5 limit-ups over 7 days [1] Group 3: Sector Performance - The innovative drug sector led the market gains, with notable performances from companies like Innovent Biologics, which saw a rise of over 9% in Hong Kong [1] - In the A-share market, Selin Medical achieved three consecutive limit-ups, while Chengyi Pharmaceutical and Weiming Pharmaceutical recorded two and three limit-ups, respectively [1] - The PCB sector also showed strength, with Shenghong Technology increasing over 6%, surpassing a market capitalization of 120 billion, and Pengding Holdings hitting the limit-up [1]

Group 1: Market Overview - The Hang Seng Index fell by 0.96%, down 232 points, closing at 23,989 points, while the Hang Seng Tech Index decreased by 1.20% [1] - The Hong Kong stock market saw a trading volume of HKD 130.6 billion in the morning session [1] Group 2: Pharmaceutical Sector - The National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, indicating that innovative drugs remain a key investment theme [1] - The Hang Seng Biotechnology Index surged by 2.79% [1] - Ascentage Pharma-B (06855) rose by 8%, Kelun-Biotech (06990) increased by 7%, and Zai Lab (09688) gained 5.21% [1] - Kangfang Biotech (09926) saw a rise of over 11% as its first dual-antibody ADC drug AK146D1 entered clinical enrollment [2] - Innovent Biologics (01801) increased by over 6% following the approval of its drug Ma Shidu Peptide for commercialization [3] - CStone Pharmaceuticals-B (02616) rose by over 11% after disclosing two dual-specific antibody drug targets, CS2013 and CS2015 [4] - Sihuan Pharmaceutical (02096) gained 4.43% after its new generation anti-VEGF monoclonal antibody "Suvetizumab" was approved for market [5] Group 3: Other Sectors - Gaming stocks continued to rise, with Macau's June gaming revenue exceeding expectations, and Citigroup predicts growth momentum will continue in the second half of the year [5] - MGM China (02282) increased by 2.6%, and Melco International Development (00200) rose by 1.75% [5] - Wheelock Properties (01997) gained 7.32% as Hong Kong's retail sales value rebounded in May, leading Morgan Stanley to upgrade the company's rating [5] - Global New Material International (06616) rose by over 5% as the acquisition of Merck's surface solutions business is nearing completion [6] - Giant Star Legend (06683) increased by over 3% after its subsidiary invested USD 8 million in the Starlight New Economy Industry Fund [7] - Kingsoft (03888) fell nearly 7% as its new game "Unrestricted Machine" entered public testing, with market attention on its performance [8]

Core Viewpoint - The management of Innovent Biologics (信达生物) aims to become a leading global biopharmaceutical company by 2030, with significant advancements in product pipelines and international market presence [1] Group 1: Product Development and Clinical Trials - IBI363, a PD-1/IL-2α-bias dual antibody, is expected to show promising results in clinical trials, with Phase I focusing on understanding mechanisms of action and Phase II targeting representative tumors for proof of concept [2] - The management anticipates that Phase III trials will advance for indications with high certainty, with first-line indications for colorectal, gastric, and lung cancers expected to yield proof of concept data by 2026 [2] - Adverse reactions for IBI363 are manageable, with a reported rate of 43.9% for grade 3 or higher adverse reactions in the 3mg/kg Q3W group, but improvements are expected as clinical experience accumulates [3] Group 2: Product Launch and Market Strategy - The recently approved Marsduo peptide is expected to see rapid market penetration, targeting adults with a BMI of 28 or higher for long-term weight control [4] - The company plans to implement a multi-channel marketing strategy for Marsduo, including hospital-based, outpatient, retail, and e-commerce channels, with projected sales of 600 million yuan in 2025 and 1.8 billion yuan in 2026 [4] Group 3: Future Outlook - The domestic non-oncology business is projected to grow significantly, driven by the approval of Marsduo and other products, with expectations of reaching 20 billion yuan in revenue by 2027 [5] - The overseas business is also expected to see revenue growth from oncology products IBI363 and IBI343, with a focus on tumor indications initially and contributions from non-oncology later [5]